A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants
一项针对健康受试者的多部分 I 期研究，旨在评估新型甲状腺激素受体β (THR-β) 激动剂 ALG-055009 治疗代谢功能障碍相关性脂肪性肝炎 (MASH) 的安全性、药效学和药代动力学。
期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.1606
Charfi, Hakim; Massetto, Benedetta; Fitzgerald, Megan; Le, Kha; Wang, Stanley; Kan-Eng, Ifong; Venkatraman, Meenakshi; Mohammad, Naqvi; Blatt, Lawrence; Lin, Tse-I; Chanda, Sushmita M; Fry, John
